Objective: Cushing’s syndrome is caused by the excessive secretion of cortisol or the intake of exogenous cortisol. Morbidity caused by osteoporosis is a major complication that cannot be ignored. We conducted a study to evaluate bone density and fracture risk factors in patients with Cushing’s syndrome. Patients and Methods: This retrospective case-control study involved 176 patients diagnosed with Cushing’s syndrome [153 female and 34 male patients] and 84 controls [72 female and 12 male patients]. Patients admitted to the clinics within the last eight years were included in the analysis. We collected demographic, clinic laboratory data, and bone densitometry measurements from electronic patient files. The classification of patients into normal, osteopenia, or osteoporosis groups is determined by their Body Mineral Density measurements based on the World Health Organization criteria. Results: Among the patients, 135 were diagnosed with Cushing’s disease and 41 with adrenal adenomas. Patients with Cushing’ syndrome showed a higher incidence of osteopenia (11.4%) and osteoporosis (2.8%) when compared to the control group. No osteoporosis cases were found in the control group, while nine cases of osteopenia were detected. Osteopenia was significantly more common in adrenal adenoma patients than in those with pituitary Cushing’s disease. Osteopenia was present in 39.1% of adrenal Cushing’s patients, with only 8.7% (n = 2) having osteoporosis. Osteopenia was observed in 11 patients (23.4%) with pituitary Cushing’s disease, while only 4 patients (8.5%) had osteoporosis. Conclusions: Osteopenia is more prevalent in patients with adrenal Cushing’s syndrome.
27 January 2025 in The Egyptian Journal of Internal Medicine
Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyte imbalances such as hypocalcemia and hypophosphatemia. Developing monitoring strategies for electrolyte abnormalities can be facilitated by the increased awareness of this interaction. We present the case of a 62-year-old female patient who developed severe, symptomatic hypocalcemia and hypophosphatemia despite having normal renal function. These abnormalities occurred concomitantly during treatment with denosumab for osteoporosis and ferric carboxymaltose for iron deficiency anemia.
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumour arising from parafollicular C cells, and serum calcitonin remains its most reliable biochemical marker. Procalcitonin (PCT), widely used in the evaluation of bacterial infections, is usually undetectable under non-infectious conditions. Persistent elevation of PCT in the absence of clinical or microbiological evidence of infection is uncommon and may represent an early clue to underlying endocrine malignancy. We report the case of a 48-year-old woman who presented with markedly elevated PCT levels (>20 ng/ml) detected during routine laboratory testing despite being asymptomatic and having normal inflammatory markers. Extensive infectious work-up was negative, and antibiotic therapy did not reduce PCT levels. Further endocrine evaluation revealed a calcitonin level >2000 ng/l, elevated carcinoembryonic antigen, and a suspicious thyroid nodule on ultrasonography. Fine-needle aspiration with calcitonin washout confirmed the diagnosis of MTC. The patient underwent total thyroidectomy with central neck dissection, and histopathology demonstrated a 4.5 cm sporadic MTC without nodal metastasis. Postoperative PCT and calcitonin levels declined markedly, supporting their parallel behaviour in relation to disease activity. This case highlights the clinical importance of considering MTC in patients with unexplained hyperprocalcitoninemia and supports the potential role of PCT as an adjunct biomarker in diagnostic evaluation and postoperative monitoring once infection has been excluded.
18 April 2026 in International Journal of Diabetes in Developing Countries
Background Diabetic neuropathy (DN) is a common microvascular complication of type 2 diabetes mellitus (T2DM), associated with chronic inflammation and metabolic dysregulation. The hemoglobin–albumin–lymphocyte–platelet (HALP) score is a composite index reflecting nutritional and inflammatory status, but its association with DN remains insufficiently characterized. Methods In this retrospective cross-sectional study, 212 patients with T2DM were evaluated. DN was defined using electrophysiological criteria. Multivariable logistic regression analysis was performed to assess the association between HALP and DN after adjustment for age, sex, diabetes duration, body mass index, and HbA1c. HALP was analyzed as a continuous variable (per 0.1-unit increase) and in quartiles. Receiver operating characteristic (ROC) curve analysis was used to evaluate model discrimination. Results Diabetic neuropathy was present in 45.2% of patients. HALP levels were significantly lower in patients with DN compared to those without DN (0.36 ± 0.18 vs. 0.72 ± 0.39, p < 0.001). In multivariable analysis, HALP remained independently associated with DN (OR per 0.1-unit increase: 0.46, 95% CI 0.35–0.58, p < 0.001). Quartile analysis showed a graded inverse association (p for trend < 0.001). The addition of HALP improved model discrimination compared to the base model (AUC 0.868 vs. 0.567). Conclusion HALP is inversely associated with diabetic neuropathy in patients with T2DM and may represent an integrated marker of metabolic and inflammatory burden.